Asahi Kasei Pharma has advanced its treatment for refractory diseases to Phase I clinical trial. 

AK1960, a novel Endothelin A (ETA) receptor antagonist, has been developed in collaboration with drug discovery company Alchemedicine, which entered a license agreement with Asahi Kasei Pharma in 2022. 

In preclinical studies, AK1960 exhibited high selectivity, potent inhibition for the ETA receptor and demonstrated efficacy in animal models for kidney diseases. AK1960 is expected to contribute to the treatment of various diseases which are difficult to control, such as refractory chronic kidney diseases.  

While Phase I studies are taking place in Japan, the programme is intended for the global market.  

“The advancement of AK1960 into Phase I trials reflects an important milestone for Asahi Kasei Pharma and demonstrates our close collaboration with Alchemedicine to address unmet medical needs,” said Yasuo Nakamura, Director and Senior Executive Officer at Asahi Kasei Pharma.  

“Since 2022, we have worked to overcome technical challenges, validate the therapeutic concept, and prepare for clinical evaluation.  

“By leveraging the expertise of Calliditas [Therapeutics] and Veloxis [Pharmaceuticals] in therapeutic development, we will continue advancing AK1960. Together, we are building a system that demonstrates scientific excellence while creating meaningful impact for real-world health settings.”